在MOGAD中接受托西利祖马布治疗:一个病例报告和文献综述
Giuseppe Schirò1,2, Salvatore Iacono1,2, Michele Andolina1,2
1Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, Palermo, Italy.
托西利祖马布 (TCZ) 在修复药失败时显示出对治疗耐火性髓寡细胞糖蛋白-免疫球蛋白G相关疾病 (MOGAD) 的承诺. 这种自身免疫性中枢神经系统疾病可能会从TCZ中受益,提供更好的结果和持续的缓解.
科学领域:
- 神经免疫学 神经免疫学
- 临床神经学 临床神经学
背景情况:
- 髓寡细胞糖蛋白-免疫球蛋白G相关疾病 (MOGAD) 是一种罕见的中枢神经系统 (CNS) 的自身免疫性脱髓化疾病.
- 目前的治疗方法,包括rituximab (RTX),并不总是有效的,导致在耐火病例中需要替代疗法.
更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD
Cystic Fibrosis: Management
Sinus disease and chronic...
